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Introduction
Gastro-oesophageal reflux disease (GORD) is defined as “a
condition which develops when reflux of stomach contents
causes troublesome symptoms and/or complications.”1 GORD
can be categorised as mild or severe; it is considered severe
when the patient experiences severe symptoms due to reflux of
gastric contents, develops complications, or both.2Complications
are commonly diagnosed endoscopically as oesophagitis with
confluent mucosal erosions.3 Other presentations of severe
GORD include peptic strictures and Barrett’s oesophagus, a
metaplasia in which parts of the native oesophageal squamous
epithelium are replaced by specialised columnar epithelium.
The main alternatives for treatment of severe GORD are
continuous treatment with a proton pump inhibitor and surgery
with fundoplication; which is the more effective is not clear.
The treatment decision largely depends on the recommendations
of the clinician.
What is the evidence of the uncertainty?
We did a systematic literature search of Medline, Cochrane,
and Web of Science to identify relevant randomised clinical
trials, meta-analyses, and systematic reviews, using the search
terms gastro-oesophageal reflux disease, proton pump inhibitors,
and fundoplication. Although severity of GORDwas not always
specified, patients eligible for long term proton pump inhibitor
or fundoplication typically have severe GORD. From the
identified studies, we did backward and forward citation tracking
to identify other relevant articles.
Reflux control
A Cochrane systematic review of a large patient sample
(n=1232) from four randomised clinical trials comparing proton
pump inhibitors and fundoplication found that reflux symptoms
were less frequent after fundoplication compared with proton
pump inhibitor treatment, but surgical patients more often had
dysphagia.2 Two of the trials included in the Cochrane review
measured recurrence of GORD, defined as the need for and an
inadequate response to increased drug treatment or the need for
added proton pump inhibitor after surgical treatment. One
(n=554) found treatment failure in 10% and 7% three years after
fundoplication and proton pump inhibitor use respectively
(P=0.25) and in 15% and 8% five years after these treatments
(P=0.048).4 5 Another randomised clinical trial (n=104) in the
Cochrane review found recurrence of reflux three years after
fundoplication or proton pump inhibitor use in 12% and 16%
respectively.6 7
Three studies in the Cochrane review measured percentage of
time with acidic oesophageal exposure (pH<4); these were not
combinable owing tomethodological differences, but the studies
overall showed a decline in both treatment groups. In the
LOTUS trial, the acidic exposure had declined in both groups
six months after treatment, from a median of 13.2% to 0.4% in
the surgical group and from 7.4% to 4.9% in the medical group
(P=0.002).8 Another randomised clinical trial showed a decline
in acidic exposure from a pre-treatment level of 10% to 2%
three years after surgery and from 10% to 4% following drug
treatment; however, the fundoplication group reported 1.4 more
heartburn-free days/week than the proton pump inhibitor group
after three years (P=0.008).7 The third trial (n=217) measuring
mean time with oesophageal pH<4 showed a decline from 13%
to 1% three months after surgery and from 10% to 4% after
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drug treatment.9Moreover, themean acidic reflux score declined
from 43 before treatment to 9 three months later in the surgical
group and from 37 to 18 in the medical group (a score >14.7
indicates clinically significant reflux).9
Overall, recurrence seems to be similar for the different
treatments. Fundoplication seems to be slightly better than
proton pump inhibitor in term of acidity control, but it carries
a higher risk of development of dysphagia after treatment.
Complications
Among patients in the Cochrane review above who underwent
fundoplication (four randomised clinical trials), six cases of
intraoperative complications were reported (equal to 2%); these
complications were damage to the liver, pleura, spleen, and
oesophagus.2 Postoperative complications occurred in 21 cases
(equal to 4%); these ranged fromwrapmigration and respiratory
tract infections to dysphagia, bloating, and strictures requiring
dilatation.2A systematic review of 293 studies of fundoplication
found intraoperative complication rates ranging from 0% to 4%
of patients and early postoperative mortality in less than 1%.10
For proton pump inhibitors, a meta-analysis of 13 case-control
studies and 12 cohort studies (n=1 936 000) indicated an
increased risk of osteoporosis and fractures (due to decreased
calcium uptake) following long term treatment (relative risk
1.3, 95% confidence interval 1.13 to 1.49).11 A meta-analysis
of seven randomised clinical trials comparing proton pump
inhibitors with placebo (n=2586) found no significant
association between proton pump inhibitor use and respiratory
infections (odds ratio 1.42, 0.86 to 2.35).12 A recent
meta-analysis including 42 observational studies (n=313 000)
found an increased risk of Clostridium difficile associated
diarrhoea with proton pump inhibitor treatment (odds ratio 1.74,
1.47 to 2.85),13 although heterogeneity was high and confounding
might have influenced the results.14 In summary, these studies
indicate a non-negligible risk of severe complications following
fundoplication, whereas complications of proton pump inhibitor
treatment are rare and less severe.
Oesophageal adenocarcinoma
GORD has been associated with oesophageal adenocarcinoma
(a cancer with poor prognosis and rapidly increasing incidence),
particularly in the United Kingdom, and the possible preventive
effect of proton pump inhibitor and fundoplication is debated.15
Any preventive effect of these treatments on the development
of oesophageal adenocarcinoma is disputed, and a recent
meta-analysis including five controlled studies of patients with
Barrett’s oesophagus (n=597) found no significant difference
in incidence rates of oesophageal adenocarcinoma after
fundoplication compared with drug treatment.16 However, this
meta-analysis included studies using various surgical techniques
and drugs; the design of the included studies also varied, they
tended to be of small cohorts without randomisation, and
confounding factors are difficult to assess and take into account
in the analysis.16 A meta-analysis of seven studies (n=2813) of
patients with Barrett’s oesophagus found a decreased risk of
oesophageal adenocarcinoma among users of proton pump
inhibitor compared with non-users (odds ratio 0.29, 0.12 to
0.79), although heterogeneity was high.17 Thus, no controlled
comparisons are available for surgery, so drawing clear
conclusions about the effects of either surgery or drug treatment
on the risk of oesophageal adenocarcinoma is not possible.
Health related quality of life
The Cochrane systematic review cited above including four
randomised clinical trials (n=1232) assessed health related
quality of life and GORD specific quality of life after surgery
compared with drug treatment; however, these results were not
combinable owing to methodological differences.2All the trials
in the Cochrane review showed improved overall quality of life
and GORD associated quality of life following both drug
treatment and surgery, although they showed slightly more
improvement after fundoplication, especially for overall quality
of life.2
Cost effectiveness
In the randomised clinical trials included in the Cochrane review,
drug treatment was more cost effective than surgery after one
year of treatment.2 A five year follow-up of one of the included
trials concluded that fundoplication is costly in the short term
but might be a cost effective treatment in the long term;
however, more data on long term outcomes are needed for a
valid cost effectiveness comparison to be done.18-20
Is ongoing research likely to provide
relevant evidence?
We searched ClinicalTrials.gov, the EUClinical Trials Register,
and the National Cancer Institute’s database for clinical trials
for ongoing randomised trials comparing proton pump inhibitors
and fundoplication, but we did not find any. Endoscopic
fundoplication by transoral incisionless fundoplication has
recently been introduced and has shown promising early results;
however, long term outcomes are not available and randomised
controlled trials are few, so this is difficult to evaluate. One
single blinded trial is recruiting patients; it will compare
transoral incisionless fundoplication with a sham procedure
(ClinicalTrials.gov NCT01110811).
What should we do in the light of the
uncertainty?
In summary, offer patients with severe GORD proton pump
inhibitors first line, as they are effective and carry a lower risk
of severe complications than surgery. Although the evidence
reviewed indicates that fundoplication may be associated with
less frequent reflux symptoms and less exposure to oesophageal
acid than proton pump inhibitors, the risk of severe
complications of fundoplication, including organ damage and
a low risk of mortality, must be considered. The patient’s attitude
to long term treatment is also very important, as treatment with
proton pump inhibitor for severe GORD requires long term
treatment with good compliance. If the response to adequate
doses of proton pump inhibitor after eight weeks of continuous
treatment is insufficient,21 fundoplication should be considered
a good alternative, particularly in young, physically fit patients,
as the available data suggest that surgery might be more cost
effective in the long term.
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Recommendation for further research
Is laparoscopic fundoplication better than proton pump inhibitors for symptom management and quality of life in patients with severe
gastro-oesophageal reflux disease?
Is laparoscopic fundoplication or treatment with proton pump inhibitors most cost effective in the long term?
Is transoral incisionless fundoplication a good alternative to laparoscopic fundoplication, and what are the short and long term outcomes
and complications?
The bottom line
Treat severe gastro-oesophageal reflux disease with proton pump inhibitors first line, as they are effective and carry a low risk of severe
complications compared with fundoplication
If response to proton pump inhibitors is inadequate after eight weeks, consider offering surgical treatment with fundoplication, especially
in young, physically fit patients whose treatment is likely to continue for a long time
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